Bayer files longer-acting bleeding candidate to FDA

The medication is looking to build on its existing drugs, but comes into a crowded market place

German pharma Bayer has sent its BLA to the FDA for its long-acting Hemophilia A medication BAY94-9027.

The drug, which is a site-specifically PEGylated recombinant human Factor VIII, is hoping to build on last year’s EU approval for Kovaltry (octocog alfa; BAY 81-8973), a hemophilia treatment that expanded the company's already big-selling Kogenate franchise.

Kovaltry is a new plasma-free recombinant Factor VIII product that does not use components of animal or human origin. It was approved for patients of all ages with hemophilia A, and works when used prophylactically either two or three times per week.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Kogenate, meanwhile, is given three times a week, and Bayer hopes that with BAY94-9027, it could be given less than this: In its submission the U.S. regulator, it used data out of the Protect VIII trial, where its medication showed protection from bleeds with dosing intervals when used prophylactically once every week, once every five days, and twice per week.

The idea, of course, is to incrementally lower the rates of treatment as much as possible, an attractive option for those with a bleeding disorder, and the future could come from gene therapy, which is hoping to try and remove the need for frequent dosing.

Suggested Articles

By employing heart rate signals, physical activity and sleep quality, common Fitbit trackers may be able to predict the spread of the flu.

Nanox has raised $26 million to help fuel the development and commercialization of its Star Trek-inspired digital X-ray bed.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.